Bulevirtide monotherapy for 48 Weeks in hdv patients with compensated cirrhosis and clinically significant portal hypertension.

[1]  S. Zeuzem,et al.  Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study , 2022, Journal of Hepatology.

[2]  V. de Lédinghen,et al.  Treatment with Bulevirtide in patients with chronic HBV/HDV co-infection. Safety and efficacy at month 18 in real-world settings , 2022, Journal of Hepatology.

[3]  M. Trauner,et al.  Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” study , 2022, Alimentary pharmacology & therapeutics.

[4]  F. Zoulim,et al.  Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. , 2021, Journal of hepatology.

[5]  T. Asselah,et al.  Endpoints and New Options for Treatment of Chronic Hepatitis D , 2021, Hepatology.

[6]  William M. Lee,et al.  Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America , 2021, Hepatology.

[7]  P. Lampertico,et al.  Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease , 2021, Gut.

[8]  T. Asselah,et al.  Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real‐life , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[9]  A. Berzigotti,et al.  Noninvasive Detection of Clinically Significant Portal Hypertension in Compensated Advanced Chronic Liver Disease. , 2021, Clinics in liver disease.

[10]  S. Hamid,et al.  The changing scenario of hepatitis D. , 2021, Journal of hepatology.

[11]  Yu-Chen Fan,et al.  Biomarkers for hepatitis B virus replication: an overview and a look to the future , 2020, Expert review of gastroenterology & hepatology.

[12]  W. Haefeli,et al.  48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection , 2020, Journal of Hepatology.

[13]  C. de Martel,et al.  The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis , 2020, Journal of hepatology.

[14]  M. Peppelenbosch,et al.  Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection , 2019, The Journal of infectious diseases.

[15]  A. Bertoletti,et al.  Excellent safety and effectiveness of high dose myrcludex-b monotherapy administered for 48 weeks in hdv related compensated cirrhosis: a case report of three patients. , 2019, Journal of hepatology.

[16]  M. Buti,et al.  Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. , 2019, Journal of hepatology.

[17]  F. Zoulim,et al.  Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. , 2019, Journal of hepatology.

[18]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[19]  W. Haefeli,et al.  Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection , 2018 .

[20]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[21]  Asociacion Latinoamericana para el Estudio del Higado.  EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.

[22]  G. D’Amico,et al.  Competing risks and prognostic stages of cirrhosis: a 25‐year inception cohort study of 494 patients , 2014, Alimentary pharmacology & therapeutics.

[23]  V. de Lédinghen,et al.  Determination of reliability criteria for liver stiffness evaluation by transient elastography , 2013, Hepatology.

[24]  W. Kim,et al.  Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease , 2008, Hepatology.

[25]  R. de Franchis.  Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. , 2015, Journal of hepatology.

[26]  J. Bosch,et al.  Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. , 2013, Gastroenterology.